Quantcast
Home > Quotes > LOGC

LogicBio Therapeutics, Inc. Common Stock (LOGC) Quote & Summary Data

LOGC 
$12.71
*  
0.495
4.05%
Get LOGC Alerts
*Delayed - data as of Apr. 24, 2019  -  Find a broker to begin trading LOGC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    LOGC After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 6.75 / $ 14.06
Today's High / Low
$ 13.03 / $ 12.0399
Share Volume
28,874
50 Day Avg. Daily Volume
13,989
Previous Close
$ 12.215
52 Week High / Low
$ 18 / $ 6.70
Market Cap
284,052,333
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
28,874
50 Day Avg. Daily Volume:
13,989

Trading Range

The current last sale of $12.71 is 89.70% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.03 $ 18
 Low: $ 12.0399 $ 6.70

Company Description (as filed with the SEC)

We are a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, our proprietary technology platform. Our GeneRide technology is designed to precisely integrate corrective genes into a patient's genome to provide a stable therapeutic effect. Because GeneRide is designed to have this durable therapeutic effect, we are initially targeting rare liver disorders in pediatric patients where it is critical to provide treatment early in a patient's life before irreversible disease pathology can occur. We have demonstrated proof of concept of our therapeutic platform in animal models for a number of diseases and are focusing on our lead product candidate, LB-001, for the treatment of Methylmalonic Acidemia, or MMA, a life-threatening disease that presents at birth.  ... More ...  



Risk Grade

Where does LOGC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 12.22
Open Date:
Apr. 24, 2019
Close Price:
$ 12.71
Close Date:
Apr. 24, 2019


Consensus Recommendation

Analyst Info